Objectives While morphological abnormalities of the pubovisceral muscle have been described on magnetic resonance imaging (MRI), their relevance remains unclear. This study was designed to define prevalence and clinical significance of such abnormalities in urogynaecological patients.
Design Prospective observational study.
Setting Tertiary urogynaecological clinic.
Population Three hundred and thirty‐eight consecutive women referred for urodynamic assessment.
Methods Participants underwent a clinical assessment, multichannel urodynamics and imaging with 3D translabial ultrasound. Blinded offline analysis was performed with the software 4D View (GE Kretztechnik, Zipf, Austria).
Main outcome measures Major morphological abnormalities of the pubovisceral muscle.
Results Defects of the pubovisceral muscle were found in 15.4% of parous women. They were exclusively anteromedial (uni‐ or bilateral), only occurred among women who had delivered vaginally and were associated with anterior and central compartment prolapse (all P < 0.001). There was no association with symptoms of bladder dysfunction or urodynamic findings.
Conclusions Major morphological abnormalities of the pubovisceral muscle are common in parous urogynaecological patients. They are associated with prolapse of the anterior and central compartment, but not with symptoms of bladder dysfunction or urodynamic findings.
There is evidence from the present pilot study suggesting that women with pelvic floor muscles hypertonicity and pelvic pain may respond to BOTOX injections into the pelvic floor muscles. Further research into this novel treatment of chronic pelvic pain is strongly recommended.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.